Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Documenti analoghi

• Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B
  di: Ryu Sasaki, et al.
  Pubblicazione: (2025)
• A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
  di: Tetsu Tomonari, et al.
  Pubblicazione: (2025)
• Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
  di: Takanori Ito, et al.
  Pubblicazione: (2024)
• Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI
  di: Tomoko Aoki, et al.
  Pubblicazione: (2026)
• Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma
  di: Yuichiro Suzuki, et al.
  Pubblicazione: (2025)